NeuroTherapeutics Pharma is financially backed by a well respected syndicate of venture capital investors. The company raised a $43 million Series B financing in May of 2010, which included participation from Fidelity Biosciences, MPM Capital, Novo Ventures, Pfizer Venture Investments, SR One and Thomas McNerney & Partners.
 |
 |
 |
 |
 |
 |
